1-Benzopyran-4-one antioxidants as aldose reductase inhibitors

Journal of Medicinal Chemistry

Volumn 42, Issue 11, 1999, Pages 1881-1893

  Costantino, Luca ^a   Rastelli, Giulio ^a   Gamberini, Maria Cristina ^a   Vinson, Joe A ^b   Bose, Pratima ^b   Iannone, Anna ^a   Staffieri, Mariagrazia ^a   Antolini, Luciano ^a   Del Corso, Antonella ^c   Mura, Umberto ^c   Albasini, Albano ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF SCRANTON   (United States)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZOPYRAN 4 ONE DERIVATIVE; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; BENZOPYRAN DERIVATIVE; QUERCETIN; SORBINIL; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; DIABETES MELLITUS; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INHIBITION; INHIBITION KINETICS; MOLECULAR MODEL; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ALDEHYDE REDUCTASE; ANIMALS; ANTIOXIDANTS; BENZOPYRANS; CATTLE; ENZYME INHIBITORS; HUMANS; KIDNEY; LENS, CRYSTALLINE; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MODELS, MOLECULAR; OXIDATION-REDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033519649     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980441h     Document Type: Article

References (71)

1. Larson, E. R.; Lipinski, C. A.; Sarges, R. Medicinal chemistry of aldose reductase inhibitors. Med. Res. Rev. 1988, 8, 159-186.
2. Eggler, J. F.; Larson, E. R.; Lipinski, C. A.; Mylari, B. L.; Urban, F. J. A perspective of aldose reductase inhibitors. Advances In Medical Chemistry; Jai Press: Greenwich, CT, 1993; Vol. 2, pp 197-246.
3. Sarges, R.; Oates, P. J. Aldose reductase inhibitors: recent developments. Prog. Drug Res. 1993, 40, 99-161.
4. Costantino, L.; Rastelli, G.; Cignarella, G.; Vianello, G.; Barlocco, D. New aldose reductase inhibitors as potential agents for the prevention of long-term diabetic complications. Exp. Opin. Ther. Patents 1997, 7, 843-858.
5. Porte, D.; Schwartz, M. W. Diabetes complications: why is glucose potentially toxic? Science 1996, 272, 699-700.
6. Baynes, J. W. Role of oxidative stress in development of complications in diabetes. Diabetes 1991, 40, 405-412.
7. Traverso, N.; Menini, S.; Odetti, P.; Pronzato, M. A.; Cottalasso, D.; Marinari, U. M. Diabetes affect lipid peroxidation in hepatic subcellular compartments. Society for Free Radical Research 1997, Summer Meeting, June 26-28, 1997, Abano Terme, Padova, Italy; Abstr. Book, p 77.
8. Traverso, N.; Menini, S.; Cosso, L.; Odetti, P.; Albano, E.; Pronzato, E.; Marinari, U. M. Immunological evidence for increased oxidative stress in diabetic rats. Diabetologia 1998, 41, 265-270.
9. Esterbauer, H.; Schaur, R. J.; Zollner, H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radical Biol. Med. 1991, 11, 81-128.
10. Vander Jagt, D. L.; Kolb, N. S.; Vander Jagt, T. J.; Chino, J.; Martinez, F.; Hunsaker, L. A.; Royer, R. E. Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate. Biochim. Biophys. Acta 1995, 1249, 117-126.
11. Srivastava, S.; Chandra, A.; Bhatnagar, A.; Srivastava, S. K.; Ansari, N. H. Lipid peroxidation product, 4-hydroxynonenal and its conjugate with GSH are excellent substrates of bovine lens aldose reductase. Biochem. Biophys. Res. Commun. 1995, 217, 741-746.
12. Kador, P. F.; Kinoshita, J. H.; Brittain, D. R.; Mirrlees, D. J.; Sennitt, C. M.; Stribling, D. Purified rat lens aldose reductase. Polyol production in vitro and its inhibition by aldose reductase inhibitors. Biochem. J. 1986, 240, 233-237.
13. Spycher, S.; Tabataba-Vakili, S.; O'Donnell, V. B.; Palomba, L.; Azzi, A. 4-hydroxy-2,3-trans-nonenal induces transcription and expression of aldose reductase. Biochem. Biophys. Res. Commun. 1996, 226, 512-516.
14. Spycher, S. E.; Tabataba-Vakili, S.; O'Donnell, V. B.; Palomba, L.; Azzi, A. Aldose reductase induction: a novel response to oxidative stress of smooth muscle cells. FASEB J. 1997, 11, 181-188.
15. Ansari, N. H.; Wang, L.; Srivastava, S. K. Role of lipid aldehydes in cataractogenesis: 4-hydroxynonenal-induced cataract. Biochem. Mol. Med. 1996, 58, 25-30.
16. Cappiello, M.; Voltarelli, M.; Cecconi, I.; Vilardo, P. G.; Dal Monte, M.; Marini, I.; Del Corso, A.; Wilson, D. K.; Florante, A. Q.; Petrash, J. M.; Mura, U. Specifically targeted modification of human aldose reductase by physiological disulfides. J. Biol. Chem. 1996, 271, 33539-33544.
17. Grimshaw, C. E.; Lai, C. J. Oxidized aldose reductase: in vivo factor, not in vitro artifact. Arch. Biochem. Biophys. 1996, 327, 89-97.
18. Cappiello, M.; Vilardo, P. G.; Cecconi, I.; Leverenz, V.; Giblin, F. J.; Del Corso, A.; Mura, U. Occurrence of glutathione-modified aldose reductase in oxidatively stressed bovine lens. Biochem. Biophys. Res. Commun. 1995, 207, 775-782.
19. Middleton, E.; Kandaswami, C. The impact of plant flavonoids on mammalian biology: implications for immunity, inflammation and cancer. In The flavonoids, Advances in Research since 1986; Harborne, J.B., Ed.; Chapman and Hall: London, 1994; pp 619-652.
20. Varma, S. D.; Kinoshita, J. H. Inhibition of lens aldose reductase by flavonoids. Their possible role in the prevention of diabetic cataracts. Biochem. Pharmacol. 1976, 25, 2505-2513.
21. Kador, P. F.; Sharpless, N. E. Structure-activity studies of aldose reductase inhibitors containing the 4-oxo-4H-chromen ring system. Biophys. Chem. 1978, 8, 81-85.
22. Okuda, J.; Miwa, I.; Inagaki, K.; Hone, T.; Nakayama, M. Inhibition of aldose reductases from rat and bovine lenses by flavonoids. Biochem. Pharmacol. 1982, 31, 3807-3822.
23. Chaudhry, P. S.; Cabrera, J.; Juliani, H. R.; Varma, S. D. Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem. Pharmacol. 1983, 32, 1995-1998.
24. Kador, P. F.; Sharpless, N. E. Pharmacophor requirements of the aldose reductase inhibitor site. Mol. Pharmacol. 1983, 24, 521-531.
25. Okuda, J.; Miwa, I.; Inagaki, K.; Horie, T.; Nakayama, M. Inhibition of aldose reductase by 3′,4′-dihydroxyflavones. Chem. Pharm. Bull. 1984, 32, 767-772.
26. Iinuma, M.; Tanaka, T.; Mizuno, M.; Katsuzaki, T.; Ogawa, H. Structure-activity correlation of flavonoids for inhibition of bovine lens aldose reductase. Chem. Pharm. Bull. 1989, 37, 1813-1815.
27. Wilson, D. K.; Tarie, I.; Petrash, J. M.; Quiocho, F. A. Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. Proc. Natl. Acad. Sci. U.S.A 1993, 90, 9847-9851.
28. Urzhumtsev, A.; Tete-Favier, F.; Mitscler, A.; Barbanton, J.; Barth, P.; Urzhumgtseva, L.; Biellmann, J. F.; Podjarny, A. D.; Moras, D. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure 1997, 5, 601-612.
29. Rastelli, G.; Costantino, L. Molecular dynamics simulations of the structure of aldose reductase complexed with the inhibitor tolrestat. Bioorg. Med. Chem. Lett. 1998, 8, 641-646.
30. Costantino, L.; Rastelli, G.; Vescovini, K.; Cignarella, G.; Vianello, P.; Del Corso, A.; Cappiello, M.; Mura, U.; Barlocco, D. Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors. J. Med. Chem. 1996, 39, 4396-4405.
31. Cushman, M.; Nagarathnam, D. A method for the facile synthesis of ring-A hydroxylated flavones. Tetrahedron Lett. 1990, 31, 6497-6500.
32. Shantanu, D. E.; Vimal, N. J.; Krishnamurty, H. G. A simple and efficient conversion of chalchones to dihydrochalchones. Indian J. Chem. 1994, 333, 163-165.
33. Bass, R. J. Synthesis of chromones by cyclization of 2-hydroxyphenyl ketones with boron trifluoride-diethyl ether and methane sulphonyl chloride. J. Chem. Soc., Chem. Commun. 1976, 78-79.
34. Costantino, L.; Rastelli, G.; Albasini, A. A rational approach to the design of flavones as xanthine oxidase inhibitors. Eur. J. Med. Chem. 1996, 31, 693-699.
35. Tyukavkina, N. A.; Pogodaeva, N. N. Ultraviolet absorption of flavonoids III. Ionization constants of the 5-hydroxy group in 5,N-dihydroxy flavones. Khim. Prir. Soedin. 1972, 2, 173-176.
36. a values, and fluorescence lifetimes of monohydroxyflavones and monomethoxyflavones. Ber. Bunsen-Ges. Phys. Chem. 1984, 88, 759-767.
37. Vinson, J. A.; Dabbagh, Y. A.; Serry, M. M.; Jang, J. Plasnt flavonoids, especially tea flavonoids, are powerful antioxidants using an in vitro oxidation model for heart disease. J. Agric. Food Chem. 1995, 43, 2800-2802.
38. Rastelli, G.; Vianello, P.; Barlocco, D.; Costantino, L.; Del Corso, A.; Mura, U. Structure-based design of an inhibitor modeled at the substrate active site of aldose reductase. Bioorg. Med. Chem. Lett. 1997, 7, 1897-1902.
39. Bohren, K. M.; Grimshaw, C. E.; Lai, C. J.; Harrison, D. H.; Ringe, D.; Petsko, G. A.; Gabbay, K. H. Tyrosine-48 is the proton donor and histidine-110 directs substrate stereochemical selectivity in the reduction reaction of human aldose reductase: enzyme kinetics and crystal structure of the Y48H mutant enzyme. Biochemistry 1994, 33, 2021-2032.
40. Grimshaw, C. E.; Bohren, K. M.; Lai, C. J.; Gabbay, K. H. Human aldose reductase: pK of tyrosine 48 reveals the preferred ionization state for catalysis and inhibition. Biochemistry 1995, 34, 14374-14384.
41. Wilson, D. K.; Bohren, K. M.; Gabbay, K. H.; Quiocho, F. A. An unlikely sugar substrate in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science 1992, 257, 81-84.
42. De Winter, H. L.; von Itzstein, M. Aldose reductase as a target for drug design: molecular modeling calculations on the binding of acyclic sugar substrates to the enzyme. Biochemistry 1995, 34, 8299-8308.
43. El-Kabbani, O.; Carper, D. A.; McGowan, M. H.; Devedjiev, Y.; Milton, K. J.; Flynn, T. G. Studies on the inhibitor-binding site of porcine aldehyde reductase: crystal structure of the holoenzyme-inhibitor ternary complex. Proteins 1997, 28, 186-192.
44. Jaen, J. C.; Wise, L. D.; Heffner, T. G.; Pugsley, T. A.; Meltzer, L. T. Dopamine autoreceptor agonists as potential antipsycotics. 2. (Aminoalkoxy)-4H-1-benzopyran-4-ones. J. Med. Chem. 1991, 34, 248-256.
45. Beilstein, 18, IV, 693.
46. Fitgerald, D. M.; O'Sullivan, J. F.; Philbin, E. M.; Wheeler, T. S. Ring expansion of 2-benzylidencoumaran-3-ones. A synthesis of flavones. J. Chem. Soc. 1955, 860-862.
47. Mahal, H. S.; Rai, H. S.; Venkantamaran, K. Synthetical experiments in the chromone group. Part XVI. Chalkones and flavanones and their oxidation to flavones by means of selenium dioxide. J. Chem. Soc. 1935, 866-868.
48. v-src. J. Med. Chem. 1994, 37, 3353-3362.
49. Sogawa, S.; Nihro, Y.; Ueda, H.; Mild, T.; Matsumoto, H.; Satoh, T. Protective effects of hydroxychalkones on free radical-induced cell damage. Biol. Pharm Bull. 1994, 17, 251-256.
50. Chen, F. C.; Chang, C. T. Synthesis of 7-halogenoflavones and related compounds. J. Chem. Soc. 1958, 146-150.
51. Dillard, R. D.; Carr, F. P.; McCullough, D.; Haisch, K. D.; Rinkema, L. E.; Fleisch, J. H. Leukotriene receptor antagonists. 2. The (((tetrazol-5-ylaryl)oxy)methyl)acetophenone derivatives. J. Med. Chem. 1987, 30, 911-918.
52. Miller, G. L.; Golder, R. H. Buffers of pH 2 to 12 for use in electrophoresis. Arch. Biochem. 1950, 29, 420-423.
53. Albert, A. The determination of ionization constants, 3rd ed.; Methuen Co. Ltd., 1984.
54. Slater, T. F.; Sawyer, B. C. The stimulatory effect of carbon tetrachloride and other halogenoalkanes on peroxidative reaction in rat liver fractions in vitro. Biochem. J. 1971, 123, 805-814.
55. Vinson, J. A.; Hontz, B. A. Phenol antioxidant index: comparative antioxidant effectiveness of red and white wines. J. Agric. Food Chem. 1995, 43, 401-403.
56. Ward, W. H. J.; Sennitt, C. M.; Ross, H.; Dingle, A.; Timms, D.; Mirrlees, D. J.; Tuffin, D. P. Ponalrestat: a potent and specific inhibitor of aldose reductase. Biochem. Pharmacol. 1990, 39, 337-346.
57. Tallarida, R. J.; Murray, R. B. Manual of pharmacological calculations with computer programs, 2nd ed.; Springer-Verlag: New York, 1987.
58. Gschwend, D. A.; Kuntz, I. D. Orientational sampling and rigidbody minimization in molecular docking revisited: on-the-fly optimization and degeneracy removal. J. Comput.-Aided Mol. Des. 1996, 10, 123-132.
59. Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 1982, 161, 269-288.
60. Meng, E. C.; Shoicket, B. K.; Kuntz, I. D. Automated docking with Grid-based energy evaluation. J. Comput. Chem. 1992, 73, 505-524.
61. Bayly, C. I.; Cieplak, P.; Cornell, W. D.; Kollman, P. A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J. Phys. Chem. 1993, 97, 10269-10280.
62. Cieplak, P.; Bayly, C. I.; Cornell, W. D.; Kollman, P. A. Application of the multimolecule and multiconformational RESP methodology to byopolymers: charge derivation for DNA, RNA, and proteins. J. Comput. Chem. 1995, 16, 1357-1377.
63. Shoicket, B. K.; Bodian, D. L.; Kuntz, I. D. Molecular docking using shape descriptors. J. Comput. Chem. 1992, 13, 380-397.
64. Ferrin, T. E.; Huang, C. C.; Jarvis, L. E.; Langridge, R. The MIDAS display system. J. Mol. Graph. 1988, 6, 13-27.
65. Pearlman, D. A.; Case, D. A.; Caldwell, J. W.; Ross, W. S.; Cheatman III, T. E.; Ferguson, D. M.; Seibel, G. L.; Singh, U. C., Weiner, P. K.; Kollman, P. A. AMBER 4.1; University of California: San Francisco, 1995.
66. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M., Jr.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force-field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
67. Lee, Y. S.; Chen, Z.; Kador, P. F. Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase. Bioorg. Med. Chem. 1998, 6, 1811-1819.
68. Lee, Y. S.; Hodoscek, M.; Brooks, B. R.; Kador, P. F. Catalytic mechanism of aldose reductase studied by the combined potentials of quantum mechanics and molecular mechanics. Biophys. Chem. 1998, 70, 203-216.
69. Petrash, J. M.; Tarle, I.; Wilson, D. K.; Quiocho, F. A. Aldose reductase catalysis and crystallography. Insight from recent advances in enzyme structure and function. Diabetes 1994, 43, 955-959.
70. Harrison, D. H.; Bohren, K. M.;Ringe, D.; Petsko, G. A.; Gabbay, K. H. An anion binding site in human aldose reductase: mechanistic implications for the binding of citrate, cacodylate, and glucose-6-phosphate. Biochemistry 1994, 33, 2011-2020.
71. +/NADPH and alrestatin-like inhibitors. Biochemistry 1994, 33, 7157-7165.